Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum IMB19
- Development stage
- Preclinical
- Lead developer
- ImmunoBiome
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum IMB19 (Lp IMB19) is a human-associated live biotherapeutic product (LBP) developed by ImmunoBiome Inc. for the treatment of various solid tumors. Identified using the AVATIOME screening model, Lp IMB19 modulates both innate and adaptive immunity to enhance anti-tumor responses. Its mechanism of action is primarily driven by a capsular component, a rhamnose-rich hetero-polysaccharide (RHP), which acts as a TLR2 agonist. This agonism targets macrophages, polarizing them toward an inflammatory phenotype and subsequently increasing the activity of CD8+ IFNγ+ T-cells. Furthermore, Lp IMB19 and its RHP component induce iron sequestration by activated macrophages within the tumor microenvironment, thereby depriving tumor cells of essential iron and suppressing their proliferation. Preclinical studies have demonstrated its efficacy in models of melanoma, renal cancer, non-small cell lung cancer (NSCLC), and urinary bladder cancer, particularly when used in combination with immune checkpoint inhibitors such as anti-PD-L1.
- Other names
- Lactobacillus plantarum IMB19
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on lactobacillus plantarum IMB19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum IMB19.